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Carboplatin and oxaliplatin are commonly used platinum
anticancer agents that are sold as ready-to-use aqueous
infusion solutionswith shelf lives of 2 and 3 years, respectively.
The observed rate constants for the hydrolysis of these
drugs, however, are too large to account for their long shelf
lives. We here use electrospray-trap mass spectrometry to
show that carboplatin and oxaliplatin are self-associated
at concentrations in their ready-to-use infusion solutions
(~27 mM and 13 mM, respectively) and, as expected, when
the drug concentration is reduced to more physiologically
relevant concentrations (100 lM and 5 lM, respectively) the
association equilibrium is shifted in favor of the monomeric
formsof these drugs.Using 1HNMRwemeasure the intensity
of the NH resonance of the two symmetry-equivalent NH3
molecules of carboplatin, relative to the intensity of the
c-methylene CH resonance, as a function of total drug
concentration. Then, by fitting the data to models of different
molecularity, we show that the association complex is a dimer
with a monomer–dimer association constant of K (M-1) =
391 ± 127. The work presented here shows that carboplatin
and oxaliplatin mainly exist as association complexes in
concentrated aqueous solution, a property that accounts for
the long term stability of their ready-to-use infusion solutions,
and that these association complexes may exist, to some
extent, in the blood after injection.
Carboplatin, 1, and oxaliplatin, 2, Fig. 1, are used in the clinic
to treat many types of cancer.1 These platinum anticancer agents
differ from cisplatin in that they both contain bidentate chelate
leaving ligands.1 For convenience of administration, these drugs
are sold as ready-to-use infusion solutions, which in the case
of carboplatin is a ~27 mM (10 mg ml-1) solution of platinum
complex dissolved in water alone, in water containing mannitol
or dextrose or, in some cases, in water containing a small amount
of the free ligand 1,1-cyclobutane dicarboxylate, CBDCA (e.g.,
Paraplatin–AQ, Bristol-Myers Squibb Co.).2,3 The ready-to-use
infusion solution of oxaliplatin, Eloxatin (Sanoﬁ-Aventis), is a
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Fig. 1 Structures of carboplatin and oxaliplatin.
~13 mM (5 mg ml-1) solution of the platinum complex in water.4
In the clinic, the infusion solution of either drug is diluted to the
required concentration, usually in 5%aqueous dextrose or glucose,
and the resulting solution is administered into the blood of the
patient in chemotherapy. An interesting property of these ready-
to-use infusion solutions, and one that allows successfulmarketing
of the product, is that their shelf lives are quite long (2 years for
carboplatin and 3 years for oxaliplatin).3,4 Analysis of ready-to-use
infusion formulations of carboplatin showed that drug loss with
time is relatively modest and independent of the presence of excess
CBDCA ligand with losses ranging from 3.09% after 5 months to
7.28% after 78 months.2 The degradation products of 1 in the
infusion solutions are ring-opened structures and hydroxo/aquo
species not having the dicarboxylate ligand.2
An interesting observation concerning the aqueous stability of
carboplatin is that the reported pseudo-ﬁrst-order rate constant
for the hydrolysis of the drug in water at 37 ◦C spans an unusually
large range, k ~5 ¥ 10-7 s-1 to k < 10-9 s-1, and only the latter
value is consistent with the observed high stability of the ready-
to-use infusion solutions.5–8 Earlier, we used 110 mM 15N-labeled
carboplatin and [1H,15N] HSQC NMR to obtain a hydrolysis
rate constant for the drug of k ~5 ¥ 10-7 s-1 (37 ◦C),5 which
agrees very well with the rate constant at 37 ◦C obtained by
Brandsˇteterova´ and coworkers, who used HPLC and ~300 mM 1
to study the hydrolysis kinetics.6 These investigators also reported
that the hydrolysis rate decreases with temperature, with k ~10-8
s-1 at 25 ◦C.6 In another study, Tobe and coworkers measured the
hydrolysis rate constant of ~500 mM carboplatin ﬁnding that k <
10-8 s-1 at 25 ◦C,7 while Sadler and coworkers used 1H NMR and a
high concentration of 1, 20 mM, to ﬁnd that k< 10-9 s-1 at 37 ◦C.8
Collectively, these results show that the rate constant for hydrolysis
of 1 is highly dependent on the starting concentration of drug
in solution. Low concentrations, which mimic the concentration
of carboplatin in the blood of patients receiving chemotherapy
This journal is © The Royal Society of Chemistry 2011 Dalton Trans., 2011, 40, 4821–4825 | 4821
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(~100 mM), produce large rate constants and high concentrations
of 1 (20 mM), which simulate the concentration of drug in ready-
to-use infusion solutions, give a small rate constant for hydrolysis.
More recently, we found that the rate constant for the reaction of
5 mM 15N-labeled carboplatin in 23.8 mM carbonate buffer (pH
8.4) at 37 ◦C is k = ~5 ¥ 10-7 s-1,9 which is approximately an order of
magnitude smaller than that measured using 110 mM 15N-labeled
carboplatin.5 The rate constants for the reaction of 5 mM and
110 mM 1 in 0.5 M carbonate buffer (pH 8.6), however, are the
same.9 While the literature on the hydrolysis of oxaliplatin is not
extensive, Jerremalm, et al.10 reported that the hydrolysis of 24 mM
oxaliplatin at 37 ◦C inHEPES buffer is 1.2 ¥ 10-6 s-1, a value which
is much too large to account for the long shelf life (3 years) of the
13 mM ready-to-use aqueous infusion solution of oxaliplatin.
In the case of the hydrolysis of 1 and 2 a dicarboxylate
chelate ligand is displaced in a stepwise manner by the attacking
nucleophile, which is water. Since it is well known that substitution
reactions of square planar complexes of Pt(II) occur through an
associative mechanism involving the formation of a 5-coordinate
intermediate,1 the ﬁrst step in the ligand displacement reaction is
the attack of awatermolecule onPt(II) via the z-axis of the complex
(the ligands occupy the x, y plane). Consideration of the X-ray
structure of carboplatin11,12 shows that the a (b) methylene groups
of the cyclobutane ring of the CBDCA ligand are positioned near
the z-axis of the complex and, since the chelate ring is in motion
in solution, the methylene hydrogen atoms could impede a water
molecule from attacking the platinum ion via both the + and -z
axis of the complex.While this potential blocking effect could lead
to reduced hydrolysis rates for carboplatin, oxaliplatin, which has
conformationally ﬁxed DACH and oxalate ligands, is devoid of a
similar structural feature that would restrict a watermolecule from
attacking the Pt(II) ion via the z-axis of the complex. All of the
atoms of the oxalate chelate ring of oxaliplatin are nominally in
the metal–donor plane, while the atoms of the chiral trans DACH
ligand do not deviate far from this plane.
A striking feature of both 1 and 2 in the solid state, is that indi-
vidual drug molecules are connected to each other through an ex-
tensive network of intermolecular hydrogen bonds in three dimen-
sions which could play a role in the concentration dependence of
the hydrolysis rate of these drugs.11,13 In the case of carboplatin, the
hydrogen bonds are between the ammonia molecules of one com-
plex and the oxygen atoms of the dicarboxylate CBDCA ligand of
neighboring complexes. For oxaliplatin, the H-bonds are between
the aminehydrogenatomsof theDACHligandof one complex and
the oxalate oxygen atoms on adjacent complexes. Since elements
of this hydrogen bond network could persist in concentrated
aqueous solutions, association complexes of themonomeric forms
of the compounds could be present in ready-to-use infusion
solutions which, because of the steric constraints of the structure,
may be the reason why high concentrations of these drugs are
resistant to hydrolysis. From transition state theory, the presence
of intermolecular associations would cause a large free energy of
activation, DG‡, leading to the activated complex which would
reduce the rate of conversion of the intact drugs to their hydrolysis
products through a decrease in the hydrolysis rate constant, k.1
We here use electrospray-trap mass spectrometry to show
qualitatively that carboplatin and oxaliplatin self-associate at
concentrations that exist in their ready-to-use infusion solutions
(27 mM and 13 mM, respectively) but at lower, more physiolog-
Table 1 Observed and calculated molecular masses for 27 mM carbo-
platin and 13 mM oxaliplatin
Peak Carboplatin compound Observed mass Calculated mass
1 [Pt(NH3)2(CBDCA)] + H+ 367.6–376 372.2
2 [Pt(NH3)2(CBDCA)] + Na+ 387.1–395.0 394.2
3 {[Pt(NH3)2(CBDCA)]}2 + H+ 740.1–747.1 743.5
4 {[Pt(NH3)2(CBDCA)]}2 + Na+ 761.6–769.1 765.5
Peak Oxaliplatin compound Observed mass Calculated mass
1 [Pt(R,R-DACH)(ox)] + H+ 397.1–402.1 398.3
2 [Pt(R,R-DACH)(ox)] + Na+ 419.0–423.1 420.3
3 {[Pt(R,R-DACH)(ox)]}2 + H+ 793.1–799.1 795.6
4 {[Pt(R,R-DACH)(ox)]}2 + Na+ 817.1–821.1 817.6
5 {[Pt(R,R-DACH)(ox)]}3 + Na+ 1212.2–1216.2 1214.8
ically relevant concentrations (100 mM and 5 mM, respectively),
these platinumdrugs donot self-associate to the same extent, Fig. 2
and 3. Positive electrospray ionization was performed on a Bruker
12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source
(COSMIC Lab, Norfolk, VA). Carboplatin, 1, and oxaliplatin,
2, were purchased as solids from Sigma–Aldrich (St. Louis, MO)
and prepared in dH2O. Peaks (m/z) corresponding to 1H+, 1Na+,
(1)2H+ and (1)2Na+ can be seen and are labeled for clarity in
the spectra of the 27 mM and 100 mM aqueous solutions of
carboplatin, Fig. 2A and B, respectively. However, it is clear that in
the 100 mM carboplatin solution the 1 dimer (m/z = 742) is much
less predominant than it is in the 27mMsolution. InFig. 3A, peaks
for 2H+, 2Na+, (2)2H+, (2)2Na+ and (2)3Na+ are present in the spec-
trum of the 13 mM aqueous solution of oxaliplatin. However, of
these four peaks, only 2H+, 2Na+ are present in the spectrum of the
5 mM oxaliplatin solution, Fig. 3B. Peak assignments for 27 mM
carboplatin and 13mMoxaliplatin are given in Table. 1.While it is
possible that a dimer or a higher order association complex could
occur via Pt–Pt interactions, as is the case of the platinum blues,
the fact that the solutions are colorless and lack the characteristic
Fig. 2 Mass spectrum of 27 mM carboplatin, 1, in water (A) and of
100 mM carboplatin, 1, in water (B).
4822 | Dalton Trans., 2011, 40, 4821–4825 This journal is © The Royal Society of Chemistry 2011
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Fig. 3 Mass spectrum of 13 mM oxaliplatin, 2, in water (A) and of 5 mM
oxaliplatin, 2, in water (B).
intense charge-transfer band of the Pt–Pt interaction indicates that
close platinum contacts are absent in the associated species.
In 1996, Embree and coworkers detected the carboplatin dimer
using liquid chromatography-mass spectrometry and ~300 mM
carboplatin.14 These investigators used formic acid in the mobile
phase which, since formic acid would be expected to break
hydrogen bonds, is evidence for the high stability of the dimer.
Using mass spectrometry, Guo and coworkers observed the dimer,
trimer, and tetramer forms of carboplatin in a ~3 mM aqueous
solution of carboplatin,15 and the carboplatin dimer was later
observed byVivekanandan et al. and by us.16,17 Guo and coworkers
suggested that these species could form in aqueous solution
through self-association or they could be artifacts of the mass
spectrometry measurement.16 We also suggested that the inability
of mesoporous silica to adsorb signiﬁcant amounts of carboplatin
from concentrated solutions of the drug was due to an associated
form of the drug which is too large to enter the pore of the
nanomaterial.17
Using freshly prepared stock solutions of 1 in 25 mM HEPES
buffer, pH 7.4, H2O/D2O (90/10) we demonstrate that as the
carboplatin concentration in solution is decreased, the 1H NMR
signal at d 4.17 ppm, associated with the two symmetry-equivalent
NH3 molecules of 1, decreases in intensity relative to the signal at
1.8 ppm (the g-methylenes of the cyclobutane ring of 1), Fig. 4. All
1D 1H spectrawere recorded at 25 ◦ConaBrukerAvance 500MHz
NMRequippedwith a 5mm inverse detection gradient probe. The
pulse sequence usedwasWatergate water suppressionwith a sweep
width of 12 ppm, relaxation delay of 10 s, and a delay for binomial
water suppression of 200 ms. Sixteen scans were acquired for each
concentration, and each spectrum was baseline corrected from 4.5
to 1.5 ppm. The integration module of Bruker’s Topspin program
was used to determine the relative intensities of the peaks at 4.17
ppm; the intensity of the peak at 1.8 ppm was calibrated to one for
each concentration. In order to determine the fraction by which
the NH3 peak intensity is suppressed due to the pulse sequence,
the excitation proﬁle for the Watergate water suppression pulse
Fig. 4 1H NMR spectra of 27 mM, 5 mM, 2.5 mM and 1 mM (from
bottom to top) carboplatin, 1, in 25mMHEPES buffer, pH 7.4, H2O/D2O
(90/10). The proton resonances ofHEPES occur in the range 2.6–3.8 ppm.
sequence was mapped. At ~280 Hz to the high ﬁeld side of the
transmitter offset (the location of theNH3 resonance), a resonance
is suppressed by 0.5. Thus, actual intensities for theNH3 resonance
were obtained by multiplying the observed peak intensities for the
resonance by two. The estimated error in the measured intensities
was determined to be ±10%.
The intensities of the peaks at 4.17 ppm (relative to the g-
methylene resonance) in 27 mM, 5 mM, 2.5 mM, and 1 mM
carboplatin solutions are 2.44 (with and without HEPES buffer,
data for the latter not shown), 1.88, 1.46 and 1.32, respectively,
showing that a decrease in concentration of 1 causes a decrease in
the intensity of the resonance at 4.17 ppm relative to themethylene
peak. Observation of the ammonia NH resonances of 1 in water
shows that these protons are in slow exchange on the NMR time
scale, which is most likely due an association complex that blocks
or slows the exchange of the protons with solvent.
The number of carboplatin molecules in the association com-
plex, m, and the association equilibrium constant, K, can be
estimated as follows: since the intensity of the 4.17 ppm peak,
normalized to the 1.8 ppm peak, would be 3.0 if all the carboplatin
were in the associated form (it is assumed that the NH’s do not
exchange with the small amount of deuterium present in the sys-
tem), dividing the normalized intensity by 3.0 gives f , the fraction
of the carboplatin that is in the complex. If the total carboplatin
concentration is C0, the concentration of the association complex
is f C0/m, and the concentration of unassociated monomer is C0
- fC0 since each complex contains m monomers. The association
equilibrium is written K
fC m
C fC m
=
−
0
0 0
/
( )
To determine m, we calculate K for each C0, using m = 1, 2, 3 or
4, and determine which value of m yields the most constant value
of K. The results are shown in Table 2.
For each value of m, we calculate the average and the standard
deviation of the four values of K, and then obtain the relative
standard deviation by dividing the standard deviation by the
average. Constancy of K means small relative standard deviation.
For m = 1, 2, 3 and 4, the relative standard deviations are 0.82,
0.32, 1.23, and 1.76. The clear choice is m = 2, suggesting that
This journal is © The Royal Society of Chemistry 2011 Dalton Trans., 2011, 40, 4821–4825 | 4823
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Table 2 Calculations to determine m, number of carboplatin molecules in the association complex and K , equilibrium constant for complex formation
C0 (mM) Intensitya f = Intensitya/3 K , m = 1 K , m = 2 K , m = 3 K , m = 4
27.0 2.44 0.814 4.38 436 5.78 ¥ 104 8.64 ¥ 106
5.0 1.88 0.626 1.67 448 1.60 ¥ 105 6.40 ¥ 107
2.5 1.46 0.486 0.95 368 1.91 ¥ 105 1.11 ¥ 108
1.0 1.32 0.440 0.79 702 8.35 ¥ 105 1.12 ¥ 109
a Intensity is the intensity of the NH3 resonance of carboplatin relative to the g-methylene resonances of the drug.
the association complex is a carboplatin dimer, consistent with
the earlier work of Embree and coworkers.14 The calculated value
of the association constant K for the dimer is the average ± the
standard deviation, i.e. K (M-1) = 391 ± 127. With this value of
K, the concentration of dimer in the 27 mM ready-to-use infusion
solution is 11.0 mM, and more than 81% of the carboplatin is in
the dimeric association complex.
The NH 1H NMR signal at d 4.17 ppm is the same resonance
employed in 2D [1H, 15N] HSQC NMR studies involving a
physiologically relevant concentration of carboplatin in carbonate
buffer,9 and in culture medium containing human cancer cells.18
Since culture medium is similar in composition to blood, the
dimeric form of 1 may also be present in the blood of patients
receiving carboplatin in chemotherapy.
Earlier, we measured the rate of reaction of carboplatin in
carbonate buffer by monitoring the intensity of the NH peak with
[1H,15N] NMR and, in a separate NMR study, the intensity of
the a,b-methylenes of the cyclobutane ring with 1D 1H NMR.9
Since the intensity of the NH resonance in the HSQC NMR
spectrum is from only the associated form and the intensity of
the methylene proton resonance is from all of the forms, obtaining
the same reaction rates from these different NMR experiments
implies that concentration of the dimer is small relative to that
of the monomer in the [1H, 15N] HSQC NMR experiment, i.e.,
when the concentration of the dimer is negligibly small, intensity
changes with time for both NMR experiments must be the
same.
Formulating stable ready-to-use infusion solutions of the
platinum anticancer drugs is a challenging task. Since these
compounds exhibit their cytotoxic effects by losing coordinated
ligands and reacting with DNA and protein targets in the cell,
they are prone to reaction with nucleophiles, especially water,
present in commercial formulations of the drugs. In the case of
carboplatin and oxaliplatin, it was found that high concentrations
of the drugs in water prevented hydrolysis thus allowing ready-
to-use solutions of these agents to be made with “shelf lives”
that were acceptable for commercial application. In the case of
cisplatin, the integrity of the compound in ready-to-use infusion
solutions is maintained by the co-addition of sodium chloride
to give a salt concentration of 154 mM (normal saline) which
prevents the dichloro form from converting to more toxic aqua
species through Le Chaˆtelier’s principle. Interestingly, the crystal
structures of the alpha and beta forms of cisplatin reveal elaborate
three-dimensional hydrogen-bonded networks.19 Intermolecular
N–H–Cl hydrogen bonding in the solid state and the observation
of [1H, 15N] HSQC NMR spectra for this drug under a variety
of solution conditions, including culture media, suggest that self-
association of cisplatin may be possible as well.19,20
From the data and arguments given above, we show that
carboplatin exists in a monomer–dimer equilibrium and suggest
that oxaliplatin is also self-associated in concentrated aqueous
solution. While the nature of the intermolecular interaction is
different, drug–drug self-association in water has been found
for the anticancer drug doxorubicin,21 and the serotonin 5HT3
receptor antagonist dolasetron, which is used to treat nausea
and vomiting that sometimes follow chemotherapy.22 Since self-
association processes are inherently concentration dependent, a
decrease in concentration, as would occur when drug is diluted
prior to its administration to the patient, shifts equilibria in favor
of themonomeric form. In fact, the packaging insert for Paraplatin
states that when the formulation is diluted in either 5% dextrose
in water or 0.9% NaCl, carboplatin is stable for only 8 h at rt.23
While dilution would be expected to drive the equilibrium toward
the monomeric form, association complexes of carboplatin, ox-
aliplatin and perhaps also cisplatin could be circulating in blood
during chemotherapy, which would have far reaching implications
for the transport, uptake and possibly the molecular mechanism
of action of these platinum anticancer drugs.
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